ProBioGen Launches Unique Portfolio of Engineered High-Performance Cell Lines
Published: Monday, November 12, 2012 Last Updated: Monday, November 12, 2012
Royalty-free biopharmaceutical CHO production cell lines, individually optimized for enhanced ADCC activity, adjusted galactosylation levels and/or increased production of the target antibodies or proteins.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.